Arcutis Biotherapeutics, Inc.
NASDAQ:ARQT · NASDAQ Global Select
-$0.51 today
Vol 5.46M · Avg 1.61M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-8.5%
avg -58.1%
ROIC
-4.0%
avg -58.4%
ROA
-3.7%
avg -54.8%
Analysis
ROA is currently the strongest return metric at -3.7% versus its period average of -54.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Todd Franklin Watanabe | President, Chief Executive Officer & Director | $1.31M | — | 58 | $720,755.00 | 0.58% |
L. Todd Edwards | Executive Vice President & Chief Commercial Officer | $897,205.00 | — | 62 | $720,755.00 | 0.58% |
Patrick E. Burnett | Executive Vice President & Chief Medical Officer | $883,376.00 | — | 54 | $16,667.00 | 0.01% |
Masaru Matsuda | Executive VP, Chief Legal Officer & Corporate Secretary | $787,699.00 | — | 55 | $127,573.00 | 0.10% |
Latha Vairavan | Senior Vice President & Chief Financial Officer | $644,904.00 | — | 48 | $85,978.00 | 0.07% |
Bethany Dudek | Chief Technical Officer | $584,551.00 | — | — | — | — |
Bhaskar Chaudhuri | Co-Founder & Director Emeritus | $60,054.00 | — | 71 | $20,568.00 | 0.02% |
Douglas DiRuggiero DMSC | Advanced Practitioner | — | — | — | — | — |
Jeff Kiekhofer | VP & Controller | — | — | — | — | — |
Rajvir Madan | Chief Digital & Technology Officer | — | — | — | — | — |
Steve Arias | Vice President of Compliance & Privacy | — | — | — | — | — |
Amanda Sheldon | Head of Corporate Communications | — | — | — | — | — |
Brian Schoelkopf | Head of Investor Relations | — | — | — | — | — |
Aleen Hosdaghian | Vice President of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
85
$17.01M
Net Sentiment
$17.01M
Net selling
Most Active
Burnett Patrick
20 transactions
1–10 of 85
Analysis
Insiders reported 0 buys worth $0.00 and 85 sells worth $17.01M over the last 12 months. That adds up to net selling of $17.01M. Burnett Patrick was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.17B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.39B
Legend Biotech Corporation
NASDAQ:LEGN
$5.36B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Amicus Therapeutics, Inc.
FOLD
$4.55B
Celcuity Inc.
NASDAQ:CELC
$4.20B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Disc Medicine, Inc.
NASDAQ:IRON
$2.69B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Who manages ARQT?
Arcutis Biotherapeutics, Inc. (ARQT) lists 14 active executives. The top listed executive is Douglas DiRuggiero DMSC, Advanced Practitioner.
Are ARQT insiders buying or selling?
Recent insider activity shows net buying of $4.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.